Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.

Escherichia coli FimH adhesin mediates binding to the bladder mucosa. In mice, a FimH vaccine protects against bacterial challenge. In this study, 4 monkeys were inoculated with 100 microgram of FimCH adhesin-chaperone complex mixed with MF59 adjuvant, and 4 monkeys were given adjuvant only intramuscularly. After 2 doses (day 0 and week 4), a booster at 48 weeks elicited a strong IgG antibody response to FimH in the vaccinated monkeys. All 8 monkeys were challenged with 1 mL of 108 E. coli cystitis isolate NU14. Three of the 4 vaccinated monkeys were protected from bacteruria and pyuria; all control monkeys were infected. These findings suggest that a vaccine based on the FimH adhesin of E. coli type 1 pili may have utility in preventing cystitis in humans.

[1]  D. Scholes,et al.  Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. , 1999, JAMA.

[2]  K. Jansen,et al.  Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. , 1997, The Journal of infectious diseases.

[3]  E. Sokurenko,et al.  Diversity of the Escherichia coli Type 1 Fimbrial Lectin , 1997, The Journal of Biological Chemistry.

[4]  S. Langermann,et al.  Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. , 1997, Science.

[5]  R. Möllby,et al.  Evaluation of the Phene Plate generalized microplate for metabolic fingerprinting and for measuring fermentative capacity of mixed bacterial populations , 1997, Journal of applied microbiology.

[6]  C. Svanborg,et al.  Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Hughes,et al.  A prospective study of risk factors for symptomatic urinary tract infection in young women. , 1996, The New England journal of medicine.

[8]  H. Mobley,et al.  Urinary tract infections : molecular pathogenesis and clinical management , 1996 .

[9]  P van Hoogevest,et al.  MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. , 1995, Pharmaceutical biotechnology.

[10]  M. Powell,et al.  Vaccine Design , 1995, Pharmaceutical Biotechnology.

[11]  T. Hooton,et al.  Management of urinary tract infections in adults. , 1993, The New England journal of medicine.

[12]  J. Pinkner,et al.  FimC is a periplasmic PapD-like chaperone that directs assembly of type 1 pili in bacteria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Siitonen,et al.  Expression of P, type-1, and type-1C fimbriae of Escherichia coli in the urine of patients with acute urinary tract infection. , 1987, The Journal of infectious diseases.

[14]  A. Schaeffer,et al.  Regulation of production of type 1 pili among urinary tract isolates of Escherichia coli , 1986, Infection and Immunity.

[15]  A. Schaeffer,et al.  Role of type 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli , 1985, Infection and immunity.

[16]  J. Winberg,et al.  THE PERIURETHRAL AEROBIC FLORA IN GIRLS HIGHLY SUSCEPTIBLE TO URINARY INFECTIONS , 1976, Acta Paediatrica Scandinavica.